{
    "nct_id": "NCT05403385",
    "official_title": "A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination with Carboplatin and Pemetrexed in Adults with Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy",
    "inclusion_criteria": "* Confirmed diagnosis of metastatic (Stage IV) or locally advanced, unresectable (Stage III) NSCLC of nonsquamous pathology\n* Measurable disease as defined by RECIST v1.1\n* PD-L1 expression status available at or after the time of diagnosis. All levels of expression are eligible.\n* Existing biopsy taken within 4 years prior to entering trial or provide fresh biopsy where safe and feasible\n* At least 12 weeks of treatment with only 1 anti-PD-(L)1 agent (mono or with IO combo) in the metastatic setting, OR at least 12 weeks of anti-PD-(L)1 agent (mono or with IO combo) following CRT in the unresectable, Stage III setting\n* ECOG performance status of 0 to 1.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Symptomatic central nervous system (CNS) metastases or leptomeningeal disease.\n* EGFR, ALK, or ROS1 mutation.\n* Autoimmune disease requiring systemic treatment or immunodeficiency requiring concurrent use of systemic immunosuppressants or corticosteroids\n* Hepatitis B or C infection unless adequately treated with no detectable viral load; Human immunodeficiency virus (HIV) unless well-controlled disease on therapy.\n* History of life-threatening toxicity related to prior immune therapy\n* Uncontrolled or significant cardiovascular disease\n* Pregnant or breast-feeding\n* Lack of agreement to use highly effective method of contraception during treatment and for 6 months after the last administration of chemotherapy",
    "miscellaneous_criteria": ""
}